Eventide Asset Management - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 135 filers reported holding AMYLYX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$20,449,285
-15.1%
1,116,8370.0%0.37%
-9.6%
Q2 2023$24,090,174
+79.3%
1,116,837
+143.8%
0.41%
+64.8%
Q1 2023$13,439,304
+45.5%
458,054
+83.2%
0.25%
+35.7%
Q4 2022$9,237,500250,0000.18%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Bain Capital Life Sciences Investors, LLC 2,756,050$35,415,0003.44%
Boxer Capital, LLC 2,200,000$28,270,0001.45%
Alpha Wave Global, LP 617,220$7,931,0000.72%
Ikarian Capital, LLC 396,654$5,097,0000.67%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 768,603$9,877,0000.58%
Ikarian Capital, LLC 250,000$3,213,0000.42%
683 Capital Management, LLC 677,714$7,685,0000.41%
Perceptive Advisors 1,474,107$18,942,0000.38%
VIKING GLOBAL INVESTORS LP 7,170,536$92,141,0000.37%
Rock Springs Capital Management LP 998,307$12,828,0000.32%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders